ASH 2017

Q&A With Martin Dreyling, MD, PhD, on Non-Hodgkin Lymphoma Research Presented at ASH

Q&A With Martin Dreyling, MD, PhD, on Non-Hodgkin Lymphoma Research Presented at ASH

By

Dr Dreyling, professor of medicine at the University of Munich Hospital, discusses research presented at the 2017 ASH Annual Meeting likely to have a clinical impact among patients with NHL.

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

By

Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.

Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

By

The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

By

Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.

PET-CT Alone May Not Distinguish Richter Transformation in CLL

PET-CT Alone May Not Distinguish Richter Transformation in CLL

By

Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

By

Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

By

The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

By

A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

By

Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

By

Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.

Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma

Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma

By

Patients who presented with an MRD level below 10-6 had a significantly improved PFS compared with patients who were above this threshold.

Nilotinib Dose, Frequency Reduction Maintains Efficacy in Chronic Myeloid Leukemia

Nilotinib Dose, Frequency Reduction Maintains Efficacy in Chronic Myeloid Leukemia

By

Researchers analyzed the outcomes of 67 patients with BCR-ABL1-positive CML in chronic phase who had an MMR on nilotinib twice daily and who then switched to a once-daily reduced-dose regimen.

Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia

Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia

By

Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.

Elotuzumab Meets Primary Endpoint of ORR for Newly Diagnosed Multiple Myeloma

Elotuzumab Meets Primary Endpoint of ORR for Newly Diagnosed Multiple Myeloma

By

Ninety-five percent of patients received elotuzumab at the increased rate of 5 mL/min without any incidence of IR.

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

By

Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.

Acalabrutinib Yields Promising Response Rates in Relapsed/Refractory Mantle Cell Lymphoma

Acalabrutinib Yields Promising Response Rates in Relapsed/Refractory Mantle Cell Lymphoma

By

The median time to response (TRR) was 1.9 months. The median duration of response (DoR) was not reached, though the 12-month DoR rate was 72% (95% CI, 62-80%).

Long-term Effects of Midostaurin Maintenance Are Unknown in <i>FLT3</i>-mutated AML

Long-term Effects of Midostaurin Maintenance Are Unknown in FLT3-mutated AML

By

At the end of maintenance, 57% and 64% of patients remained in the midostaurin arm or the placebo arm, respectively. There were 16 relapse events after maintenance in the midostaurin arm and 7 relapses and 2 deaths in the placebo arm.

Imatinib Increases Complete Response Rate, Decreases HSCT Allocation in Pediatric ALL

Imatinib Increases Complete Response Rate, Decreases HSCT Allocation in Pediatric ALL

By

Based on findings from previous studies (COG AALL0031 and EsPhALL 2004-2009), researchers are assessing the association of continuous imatinib plus chemotherapy with the reduced need for HSCT.

Dasatinib Is Safe and Effective in Philadelphia Chromosome-positive Pediatric ALL

Dasatinib Is Safe and Effective in Philadelphia Chromosome-positive Pediatric ALL

By

Researchers assessed the efficacy of dasatinib — a TKI that is significantly more potent than imatinib and is active even in the setting of imatinib resistance — in this patient population.

Predictors and Implications of Rituximab Maintenance Failure in Mantle Cell Lymphoma

Predictors and Implications of Rituximab Maintenance Failure in Mantle Cell Lymphoma

By

Patients who did not reach a first complete remission were twice as likely to fail rituximab maintenance therapy; patients who received autologous stem cell transplant had a decreased failure risk of 69%.

Induction to Deepen Pre-transplant Response Does Not Improve OS in Multiple Myeloma

Induction to Deepen Pre-transplant Response Does Not Improve OS in Multiple Myeloma

By

Study results suggest that many patients with multiple myeloma should proceed directly to autologous stem cell transplantation after first-line therapy.

Ibrutinib Effective As First-line Therapy for Waldenstrom Macroglobulinemia

Ibrutinib Effective As First-line Therapy for Waldenstrom Macroglobulinemia

By

Ibrutinib is used among patients with WM who have previously received treatment, but its efficacy as a first-line therapy among treatment-naive patients is unknown.

Daratumumab Plus Standard Care Doubles PFS in Newly Diagnosed Multiple Myeloma

Daratumumab Plus Standard Care Doubles PFS in Newly Diagnosed Multiple Myeloma

By

A previous study demonstrated that patients with relapsed MM have a superior PFS and greater depth of response when treated with D-VMP.

Inotuzumab Ozogamicin Plus Bosutinib May Be Safe, Effective for Relapsed/Refractory ALL and CML

Inotuzumab Ozogamicin Plus Bosutinib May Be Safe, Effective for Relapsed/Refractory ALL and CML

By

Eleven patients had a complete response: 10 had complete cytogenic remission, 8 were negative by flow cytometry, 6 had undetectable BCR-ABL. Three patients did not respond.

Imatinib Effective as Front-line Therapy for Pediatric Chronic Myeloid Leukemia

Imatinib Effective as Front-line Therapy for Pediatric Chronic Myeloid Leukemia

By

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

Q&A With Shaji Kumar, MD: Looking to the Future of Multiple Myeloma Treatment

Q&A With Shaji Kumar, MD: Looking to the Future of Multiple Myeloma Treatment

By

Cancer Therapy Advisor asked Shaji Kumar, MD, to share his thoughts about where we are now and where we are going regarding promising data and novel approaches for MM treatment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs